Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Endocrinology ; 151(8): 3675-85, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20501668

ABSTRACT

Osteoporosis is an important clinical problem, affecting more than 50% of people over age 50 yr. Estrogen signaling is critical for maintaining proper bone density, and the identification of an endogenous selective estrogen receptor (ER) modulator, 27-hydroxycholesterol (27HC), suggests a mechanism by which nutritional/metabolic status can influence bone biology. With its levels directly correlated with cholesterol, a new possibility emerges wherein 27HC links estrogen and cholesterol signaling to bone homeostasis. In these studies, we found that increasing concentrations of 27HC, both by genetic and pharmacological means, led to decreased bone mineral density that was associated with decreased bone formation and increased bone resorption. Upon manipulation of endogenous estrogen levels, many of the responses to elevated 27HC were altered in such a way as to implicate ER as a likely mediator. In a model of postmenopausal bone loss, some pathologies associated with elevated 27HC were exacerbated by the absence of endogenous estrogens, suggesting that 27HC may act both in concert with and independently from classic ER signaling. These data provide evidence for interactions between estrogen signaling, cholesterol and metabolic disease, and osteoporosis. Patients with high cholesterol likely also have higher than average 27HC, perhaps putting them at a higher risk for bone loss and fracture. More studies are warranted to fully elucidate the mechanism of action of 27HC in bone and to identify ways to modulate this pathway therapeutically.


Subject(s)
Bone and Bones/drug effects , Homeostasis/drug effects , Hydroxycholesterols/pharmacology , Selective Estrogen Receptor Modulators/pharmacology , Animals , Bone Density/drug effects , Bone Resorption/chemically induced , Bone Resorption/genetics , Bone Resorption/metabolism , Bone and Bones/metabolism , Bone and Bones/physiology , Cholestanetriol 26-Monooxygenase/genetics , Cholestanetriol 26-Monooxygenase/metabolism , Cytochrome P450 Family 7 , Estradiol/pharmacology , Female , Homeostasis/genetics , Hydroxycholesterols/metabolism , Mice , Mice, Knockout , Osteoblasts/drug effects , Osteoblasts/metabolism , Osteoblasts/physiology , Osteogenesis/drug effects , Osteogenesis/genetics , Osteogenesis/physiology , Selective Estrogen Receptor Modulators/metabolism , Steroid Hydroxylases/genetics , Steroid Hydroxylases/metabolism
2.
Mol Endocrinol ; 19(10): 2478-90, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16051662

ABSTRACT

Under the auspices of the Nuclear Receptor Signaling Atlas (NURSA), we have undertaken to evaluate the feasibility of targeting nuclear receptor-coactivator surfaces for new drug discovery. The underlying objective of this approach is to provide the research community with reagents that can be used to modulate the transcriptional activity of nuclear receptors. Using combinatorial peptide phage display, we have been able to develop peptide antagonists that target specific nuclear receptor (NR)-coactivator binding surfaces. It can be appreciated that reagents of this nature will be of use in the study of orphan nuclear receptors for whom classical ligands have not yet been identified. In addition, because the interaction of coactivators with the receptor is an obligate step for NR transcriptional activity, it is anticipated that peptides that block these interactions will enable the definition of the biological and pharmacological significance of individual NR-coactivator interactions. In this report, we describe the use of this approach to develop antagonists of the androgen receptor by targeting its coactivator-binding pocket and their use to study the coactivator-binding surface of this receptor. Based on our findings, we believe that molecules that function by disrupting the androgen receptor-cofactor interactions will have use in the treatment of prostate cancer.


Subject(s)
Androgen Receptor Antagonists , Amino Acid Sequence , Animals , Combinatorial Chemistry Techniques , Drug Design , Humans , In Vitro Techniques , Molecular Sequence Data , Peptide Library , Peptides/chemical synthesis , Peptides/chemistry , Peptides/pharmacology , Protein Binding , Receptors, Androgen/genetics , Receptors, Androgen/metabolism , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Transcriptional Activation/drug effects , Two-Hybrid System Techniques
SELECTION OF CITATIONS
SEARCH DETAIL
...